Mechanisms of reactivation of the FMR1 gene and analysis of pathways involved in the pathogenesis of fragile X syndrome: towards a drug-based therapy
- 2 Years 2010/2012
- 253.500€ Total Award
The fragile X syndrome is the most common cause of inherited mental retardation. The population prevalence of affected males is approximately 1 in 4000, and that of carrier females, at risk of having affected children, 1 in 250 or more. The syndrome is caused by a mutation of the FMR1 gene localized on the X chromosome. The mutation consists in an amplification and methylation of a DNA sequence within the promoter of the gene. This change blocks the expression of the gene, preventing the production of the FMRP protein, in spite of the fact that the coding sequence of the gene is intact. One might say that the gene is not broken; it is just switched off. We showed previously that the mutant gene can be switched back on by treating in vitro cell lines from fragile X syndrome patients with drugs that can remove the methylation from the DNA and thus relieve the block of the promoter. We also showed that regulation of the FMR1 gene activity depends not only on DNA methylation but also on epigenetic (reversible) structural changes occurring on the histones, i.e. those proteins on which the DNA double helix is wound. With the present project we intend to study in more detail the mechanisms that regulate the expression of the FMR1 gene, by: a) investigating in induced pluripotent stem cells (similar to embryonic stem cells) the factors that during development trigger those epigenetic changes that block the activity of the FMR1 gene; b) analyzing the role of small RNA molecules known to regulate gene expression; c) analyzing the effect of new drugs potentially capable of restoring the activity of the FMR1 gene. Our ultimate goal is to transfer in vivo the results obtained in vitro, hoping that this may lead to the discovery of an effective cure of the syndrome. We have recently completed in vivo clinical trials whose encouraging results suggest that that ultimate goal is attainable.
Scientific Publications
- 2016 European journal of human genetics : EJHG
Defining the role of the CGGBP1 protein in FMR1 gene expression.
- 2014 PSYCHOPHARMACOLOGY
Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development.
- 2013 Frontiers in neuroscience
The FMRP regulon: from targets to disease convergence.
- 2013 PLoS Genetics
Role of CTCF protein in regulating FMR1 locus transcription.
- 2013 The Journal of neuroscience : the official journal of the Society for Neuroscience
The Fragile X mental retardation protein regulates matrix metalloproteinase 9 mRNA at synapses.
- 2013 NEURON
CYFIP1 coordinates mRNA translation and cytoskeleton remodeling to ensure proper dendritic spine formation.
- 2012 The Journal of clinical investigation
Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics.
- 2012 BMC MEDICAL GENETICS
The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro.
- 2012 Nucleic acids research
BC1-FMRP interaction is modulated by 2'-O-methylation: RNA-binding activity of the tudor domain and translational regulation at synapses.
- 2011 Nucleic acids research
Differential usage of transcriptional start sites and polyadenylation sites in FMR1 premutation alleles.
- 2011 American journal of medical genetics. Part A
The FRAXopathies: definition, overview, and update.
- 2011 JOURNAL OF NEURODEVELOPMENTAL DISORDERS
Regulation of molecular pathways in the Fragile X Syndrome: insights into Autism Spectrum Disorders.
- 2013 Cellular and molecular life sciences : CMLS
KIF1Bß transports dendritically localized mRNPs in neurons and is recruited to synapses in an activity-dependent manner.
- 2014 JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
Molecular dynamics simulations show how the FMRP Ile304Asn mutation destabilizes the KH2 domain structure and affects its function.